Application Detail
Description of Medical Service
Molecular testing for the diagnosis of polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF) can establish the presence or absence of specific mutations known to occur in patients with these disorders. MBS item 73325 currently provides for Janus kinase (JAK2) and myeloproliferative leukaemia (MPL) gene testing in patients with PV or ET. The proposed medical service being requested is the expansion of MBS item 73325 to allow testing for calreticulin (CALR) mutations in patients with PV or ET, and testing for JAK2, MPL and CALR genes in patients with primary myelofibrosis (PMF).Description of Medical Condition
Myeloproliferative neoplasms (MPNs) are a group of disorders in which bone marrow stem cells grow and reproduce abnormally. PV, ET and PMF are MPN's.Reason for Application
Amendment to MBS itemMedical Service Type
InvestigativePrevious Application Number
1125Associated Documentation
Application Form
-Consultation Survey
Consultation Survey (PDF 168 KB)Consultation Survey (Word 70 KB)
PICO Confirmation
-Assessment Report
-Public Summary Document
Public Summary Document - March 2019 (PDF 945 KB)Public Summary Document - March 2019 (Word 216 KB)
Public Summary Document - November 2020 (PDF 882 KB)
Public Summary Document - November 2020 (Word 8334 KB)
Meetings for this Application
PASC
-ESC
8 February 20198-9 October 2020
MSAC
28-29 March 201926-27 November 2020